▁Introduction 10.375
: 6.51953125
<0x0A> 3.98046875
In 4.578125
▁a 2.93359375
▁significant 7.01171875
▁break 3.615234375
through 0.83740234375
▁for 1.1650390625
▁cancer 5.63671875
▁treatment 2.3671875
, 0.20947265625
▁British 5.375
▁bi 5.1953125
ote 0.2607421875
ch 0.338134765625
▁firm 1.2119140625
, 3.296875
▁[ 9.875
Company 5.046875
▁Name 1.10546875
], 1.8330078125
▁has 0.6376953125
▁recently 3.05078125
▁announced 0.81494140625
▁positive 5.5078125
▁results 0.4912109375
▁from 0.5361328125
▁their 3.259765625
▁experimental 4.9609375
▁cancer 2.783203125
▁drug 1.669921875
. 1.92578125
▁The 0.98681640625
▁drug 0.57373046875
▁has 2.244140625
▁shown 1.5126953125
▁prom 2.169921875
ising 0.00043892860412597656
▁effic 4.44140625
acy 0.0005669593811035156
▁in 0.80126953125
▁clin 5.03125
ical 0.007167816162109375
▁tri 0.130859375
als 0.00019037723541259766
, 1.33203125
▁bringing 6.41796875
▁hope 0.50634765625
▁to 0.552734375
▁the 2.44921875
▁millions 1.228515625
▁of 0.2294921875
▁cancer 0.93701171875
▁patients 0.184814453125
▁world 1.091796875
wide 0.01018524169921875
. 0.27587890625
▁However 4.9375
, 0.005161285400390625
▁anal 7.359375
yst 0.0251312255859375
s 0.004741668701171875
▁are 1.0986328125
▁express 4.8359375
ing 0.0004646778106689453
▁ca 0.9189453125
ution 0.002719879150390625
▁and 3.384765625
▁emphas 6.03515625
izing 0.297119140625
▁the 0.55419921875
▁need 0.35107421875
▁for 0.037261962890625
▁further 0.390869140625
▁research 1.9013671875
▁and 1.03125
▁regul 7.87890625
atory 0.00032830238342285156
▁appro 0.12420654296875
val 8.344650268554688e-05
s 1.6787109375
▁before 0.495849609375
▁considering 6.078125
▁it 2.470703125
▁a 0.68408203125
▁definit 4.81640625
ive 0.004810333251953125
▁cancer 4.0078125
▁treatment 0.375
. 0.2666015625
<0x0A> 0.36669921875
Prom 7.80859375
ising 0.0738525390625
▁C 2.966796875
lin 0.00164794921875
ical 0.0020618438720703125
▁Tri 0.65185546875
als 1.3955078125
: 2.91796875
<0x0A> 0.251708984375
[ 2.181640625
Company 0.0138702392578125
▁Name 0.008758544921875
] 0.1951904296875
' 2.908203125
s 0.0049285888671875
▁cancer 2.31640625
▁drug 0.177734375
▁has 1.591796875
▁exhib 6.38671875
ited 0.00024700164794921875
▁early 4.80078125
- 4.7578125
stage 0.111328125
▁success 2.2734375
▁in 0.0718994140625
▁clin 1.02734375
ical 0.0009436607360839844
▁tri 0.0235443115234375
als 3.337860107421875e-06
, 0.85302734375
▁providing 3.64453125
▁renew 6.05859375
ed 0.0003426074981689453
▁optim 2.55078125
ism 0.00010788440704345703
▁in 3.12890625
▁the 0.1883544921875
▁fight 1.75
▁against 0.01406097412109375
▁cancer 0.1617431640625
. 0.05670166015625
▁In 2.78125
▁a 1.09375
▁carefully 6.37109375
▁controlled 0.87060546875
▁study 0.93505859375
▁involving 2.01953125
▁several 5.67578125
▁cancer 2.943359375
▁patient 3.689453125
▁coh 1.9189453125
ort 1.7404556274414062e-05
s 0.0008273124694824219
, 0.158203125
▁the 0.204345703125
▁drug 0.360595703125
▁demonstrated 2.1484375
▁notable 5.6953125
▁effect 4.47265625
iveness 0.008209228515625
▁in 0.466796875
▁in 4.19921875
hib 0.006183624267578125
iting 0.004688262939453125
▁tum 0.6298828125
or 0.0653076171875
▁growth 0.0887451171875
▁and 0.6630859375
, 6.49609375
▁in 0.7685546875
▁some 0.1746826171875
▁cases 0.0958251953125
, 0.002349853515625
▁even 0.9208984375
▁indu 2.63671875
cing 0.0006012916564941406
▁tum 1.60546875
or 0.0240936279296875
▁regression 0.93359375
. 0.11676025390625
▁These 3.111328125
▁encourag 3.3359375
ing 0.00014710426330566406
▁results 0.32568359375
▁have 0.74853515625
▁spark 3.2890625
ed 0.00010311603546142578
▁excitement 2.5546875
▁within 3.416015625
▁the 0.0582275390625
▁medical 2.537109375
▁community 0.10943603515625
. 4.9140625
<0x0A> 1.1376953125
Me 6.8984375
chan 3.607421875
ism 0.1583251953125
▁of 0.0701904296875
▁Action 0.059051513671875
: 0.07196044921875
<0x0A> 0.01611328125
The 0.95263671875
▁success 5.7578125
▁of 0.06939697265625
▁[ 0.888671875
Company 0.00772857666015625
▁Name 0.00677490234375
] 0.037750244140625
' 0.03271484375
s 0.002532958984375
▁cancer 0.8564453125
▁drug 0.10479736328125
▁can 2.271484375
▁be 0.0704345703125
▁attributed 0.2117919921875
▁to 0.07318115234375
▁its 0.1826171875
▁unique 1.392578125
▁mechanism 0.1942138671875
▁of 0.0036773681640625
▁action 0.0011835098266601562
. 0.298095703125
▁By 2.92578125
▁target 0.95458984375
ing 0.00031948089599609375
▁specific 1.912109375
▁gen 2.29296875
etic 1.107421875
▁mut 1.05078125
ations 0.00151824951171875
▁pre 7.53125
val 0.0130462646484375
ent 0.0003161430358886719
▁in 0.046905517578125
▁various 3.611328125
▁cancer 1.935546875
▁types 0.22265625
, 0.013824462890625
▁the 0.25732421875
▁drug 0.0234222412109375
▁effectively 3.416015625
▁dis 2.61328125
rupt 0.53076171875
s 0.0003254413604736328
▁tum 1.0595703125
or 0.007472991943359375
▁cell 1.93359375
▁pro 3.048828125
l 0.00998687744140625
ifer 0.0001176595687866211
ation 0.0007643699645996094
▁and 0.421875
▁surv 3.443359375
ival 0.0015821456909179688
, 1.11328125
▁offering 5.3125
▁a 1.4267578125
▁potential 2.404296875
▁break 2.66796875
through 0.0034351348876953125
▁in 0.425048828125
▁personal 6.40625
ized 0.0574951171875
▁medicine 2.642578125
. 0.39111328125
▁Its 6.53125
▁ability 1.693359375
▁to 0.0007686614990234375
▁combat 5.59765625
▁cancer 1.6279296875
▁cells 1.8935546875
▁while 2.703125
▁minim 2.93359375
izing 0.044647216796875
▁damage 2.826171875
▁to 0.00548553466796875
▁health 0.423828125
y 0.0001270771026611328
▁cells 0.5751953125
▁sets 5.8671875
▁it 0.21875
▁apart 0.005401611328125
▁from 0.02874755859375
▁conventional 3.701171875
▁treatment 3.041015625
▁approaches 2.265625
▁like 5.4296875
▁chem 0.30419921875
other 0.0124969482421875
apy 0.007663726806640625
▁and 1.0625
▁radiation 0.1494140625
▁ther 0.8564453125
apy 0.013519287109375
. 0.45556640625
<0x0A> 0.1551513671875
Enc 7.98046875
ou 0.004970550537109375
rag 0.00905609130859375
ing 0.06866455078125
▁Pat 5.1796875
ient 0.07135009765625
▁Res 5.17578125
p 0.029632568359375
ons 4.887580871582031e-05
es 2.3365020751953125e-05
: 0.0091552734375
<0x0A> 0.0015707015991210938
The 1.37109375
▁drug 1.986328125
' 0.5576171875
s 0.0006341934204101562
▁success 2.32421875
▁stories 7.6328125
▁are 1.728515625
▁not 2.572265625
▁limited 1.3974609375
▁to 0.00856781005859375
▁labor 4.18359375
atory 0.00949859619140625
▁results 4.5625
▁alone 0.56982421875
. 0.501953125
▁Test 5.65234375
imon 0.07147216796875
ies 3.228515625
▁from 0.11102294921875
▁patients 0.501953125
▁involved 5.66015625
▁in 0.0301055908203125
▁the 2.103515625
▁clin 0.288330078125
ical 0.00037217140197753906
▁tri 0.1307373046875
als 2.9802322387695312e-06
▁further 6.01171875
▁support 3.35546875
▁the 1.2060546875
▁drug 0.64404296875
' 0.00262451171875
s 0.0009546279907226562
▁effic 0.65576171875
acy 6.4373016357421875e-06
. 0.814453125
▁Many 2.48046875
▁patients 0.61865234375
▁reported 2.12890625
▁improvements 3.3984375
▁in 0.0223846435546875
▁their 0.92919921875
▁overall 1.853515625
▁health 0.3203125
▁and 0.97998046875
▁quality 0.5498046875
▁of 0.00917816162109375
▁life 0.0008525848388671875
, 1.26171875
▁with 1.7001953125
▁some 0.76513671875
▁even 0.45166015625
▁experien 1.2333984375
cing 1.9073486328125e-06
▁long 3.310546875
- 0.012908935546875
last 2.169921875
ing 1.1801719665527344e-05
▁rem 1.5625
ission 1.923828125
. 1.4453125
▁These 2.076171875
▁remarkable 5.55078125
▁responses 3.7890625
▁are 1.9111328125
▁a 1.578125
▁be 6.921875
acon 0.0011148452758789062
▁of 0.005401611328125
▁hope 0.0185546875
▁for 0.2271728515625
▁patients 1.7236328125
▁who 2.2421875
▁have 0.4658203125
▁exha 2.421875
usted 8.702278137207031e-06
▁other 1.48828125
▁treatment 0.5703125
▁options 0.0151824951171875
. 1.685546875
<0x0A> 0.12451171875
Anal 5.76953125
yst 0.0780029296875
s 0.509765625
▁Ur 5.984375
ge 0.04290771484375
▁Ca 0.1619873046875
ution 0.0002875328063964844
▁and 5.28515625
▁Further 1.6767578125
▁Research 0.0927734375
: 0.025146484375
<0x0A> 0.0008335113525390625
Des 2.09765625
p 0.00014221668243408203
ite 6.16312026977539e-05
▁the 0.8251953125
▁positive 1.94140625
▁out 3.31640625
comes 0.11016845703125
, 2.185546875
▁anal 0.6162109375
yst 1.2993812561035156e-05
s 0.00045371055603027344
▁and 4.03515625
▁industry 3.130859375
▁exper 0.61083984375
ts 7.152557373046875e-07
▁are 0.453125
▁ur 1.7080078125
ging 0.000560760498046875
▁ca 0.0123443603515625
ution 1.1086463928222656e-05
▁and 0.5654296875
▁advoc 6.42578125
ating 0.0064544677734375
▁for 0.283203125
▁further 0.275390625
▁research 0.159423828125
▁into 2.107421875
▁the 0.72314453125
▁drug 0.37451171875
' 0.21337890625
s 0.001628875732421875
▁long 3.849609375
- 0.006183624267578125
term 0.0030307769775390625
▁effects 1.3447265625
▁and 0.89892578125
▁safety 1.3056640625
▁profile 0.66357421875
. 0.30908203125
▁Rec 7.5859375
ogn 3.1484375
izing 0.0191650390625
▁that 1.5341796875
▁clin 3.03515625
ical 0.0037441253662109375
▁tri 0.1561279296875
als 5.125999450683594e-06
▁are 0.449951171875
▁often 2.3359375
▁conducted 3.904296875
▁on 2.2890625
▁a 0.50244140625
▁relatively 3.556640625
▁small 0.0219879150390625
▁sample 0.82861328125
▁size 0.09039306640625
, 0.2281494140625
▁they 2.556640625
▁emphas 2.40234375
ize 0.0162200927734375
▁the 0.08685302734375
▁need 0.32470703125
▁for 0.0165557861328125
▁larger 2.287109375
, 1.453125
▁more 0.4833984375
▁rig 2.4765625
orous 0.00379180908203125
▁studies 0.48828125
▁to 1.1884765625
▁determine 2.73828125
▁the 1.130859375
▁drug 0.5166015625
' 0.0007729530334472656
s 0.0007357597351074219
▁true 1.634765625
▁potential 0.673828125
▁and 2.59375
▁any 4.20703125
▁potential 0.55029296875
▁ad 2.611328125
verse 4.76837158203125e-06
▁effects 0.1822509765625
. 0.256103515625
▁Additionally 2.98046875
, 0.000640869140625
▁regul 5.125
atory 0.062042236328125
▁appro 0.224609375
val 4.076957702636719e-05
▁from 3.26953125
▁the 0.85791015625
▁relevant 5.35546875
▁authorities 0.80224609375
▁is 0.79638671875
▁imper 5.25390625
ative 0.00020706653594970703
▁to 1.2353515625
▁ensure 0.73583984375
▁patient 1.798828125
▁safety 0.045928955078125
▁and 0.79345703125
▁the 3.5625
▁drug 0.79052734375
' 0.06488037109375
s 0.00010073184967041016
▁commercial 4.296875
▁vi 0.8349609375
ability 0.00012362003326416016
. 0.1953125
<0x0A> 0.1510009765625
P 4.94921875
ot 0.406494140625
ential 0.016357421875
▁Ch 5.32421875
alleng 0.0032939910888671875
es 0.0008149147033691406
▁and 2.5234375
▁Lim 3.23828125
itations 0.025970458984375
: 0.0780029296875
<0x0A> 0.00400543212890625
A 4.6015625
part 3.537109375
▁from 0.0007781982421875
▁the 0.8203125
▁concerns 4.3046875
▁over 2.845703125
▁safety 2.38671875
▁and 0.376220703125
▁long 3.0
- 0.00789642333984375
term 0.00336456298828125
▁effic 1.6220703125
acy 8.821487426757812e-06
, 0.1712646484375
▁several 4.19921875
▁challeng 1.2705078125
es 0.0013828277587890625
▁and 0.8037109375
▁limitations 0.018218994140625
▁need 3.85546875
▁to 0.0203857421875
▁be 0.0014171600341796875
▁taken 2.95703125
▁into 0.0122222900390625
▁account 0.64306640625
. 1.7919921875
▁The 1.9189453125
▁drug 0.5751953125
' 0.52783203125
s 0.0003781318664550781
▁cost 3.708984375
▁and 1.447265625
▁access 2.72265625
ibility 0.017608642578125
▁may 2.626953125
▁pose 1.8115234375
▁bar 2.255859375
riers 0.0004494190216064453
▁to 0.541015625
▁w 2.595703125
ides 7.176399230957031e-05
p 0.0006313323974609375
read 0.00017654895782470703
▁use 1.3330078125
. 0.76025390625
▁Additionally 0.44677734375
, 0.00014662742614746094
▁potential 5.22265625
▁drug 3.33203125
▁resistance 0.28759765625
▁and 1.8056640625
▁vari 7.1640625
ability 0.0093536376953125
▁in 0.406982421875
▁patient 1.095703125
▁response 0.68212890625
▁highlight 7.09375
▁the 0.296630859375
▁need 0.057159423828125
▁for 0.01088714599609375
▁deeper 7.75390625
▁investig 3.791015625
ations 0.00901031494140625
▁and 2.037109375
▁tail 4.76171875
ored 0.10186767578125
▁treatment 0.8603515625
▁strateg 1.185546875
ies 2.6226043701171875e-06
. 0.401123046875
<0x0A> 0.708984375
Look 5.70703125
ing 0.040435791015625
▁A 1.591796875
head 0.000522613525390625
: 0.037109375
<0x0A> 0.0186004638671875
[ 2.283203125
Company 0.00492095947265625
▁Name 0.0034809112548828125
] 0.0758056640625
' 0.53271484375
s 0.002819061279296875
▁cancer 0.826171875
▁drug 0.0361328125
▁shows 4.69140625
▁immense 3.982421875
▁promise 0.1656494140625
▁in 1.1455078125
▁the 1.5673828125
▁treatment 2.130859375
▁of 0.0162353515625
▁various 1.1376953125
▁cancer 1.744140625
▁types 0.057159423828125
, 1.232421875
▁providing 2.255859375
▁a 2.220703125
▁g 3.595703125
lim 0.11126708984375
mer 0.0004949569702148438
▁of 0.0006513595581054688
▁hope 0.0135040283203125
▁for 0.5380859375
▁patients 0.85986328125
▁and 1.58984375
▁health 4.90625
care 0.0821533203125
▁profession 0.97900390625
als 3.337860107421875e-06
. 3.90234375
▁While 2.560546875
▁c 8.75
aut 0.0277252197265625
ious 0.0621337890625
▁optim 0.06378173828125
ism 0.0012264251708984375
▁has 4.81640625
▁g 7.01953125
ri 0.301025390625
pped 0.00014781951904296875
▁the 0.06365966796875
▁field 5.66796875
, 0.2215576171875
▁it 2.736328125
▁is 0.71142578125
▁essential 1.8564453125
▁to 0.46875
▁conduct 1.669921875
▁further 0.361328125
▁studies 1.8759765625
▁and 0.62060546875
▁obtain 4.08203125
▁regul 0.15576171875
atory 4.017353057861328e-05
▁appro 0.00801849365234375
val 2.276897430419922e-05
▁to 3.47265625
▁fully 2.279296875
▁compreh 4.97265625
end 0.0005517005920410156
▁the 1.4150390625
▁drug 0.26904296875
' 0.0086212158203125
s 0.0007634162902832031
▁potential 0.59326171875
▁benefits 1.36328125
▁and 0.431396484375
▁ris 0.9912109375
ks 2.0742416381835938e-05
. 0.1685791015625
▁The 2.884765625
▁collaboration 7.5390625
▁between 0.5029296875
▁the 2.677734375
▁bi 2.185546875
ote 0.0268707275390625
ch 0.139404296875
▁company 1.8388671875
, 2.404296875
▁medical 3.484375
▁community 1.5009765625
, 0.1522216796875
▁and 0.09954833984375
▁regul 0.336181640625
atory 0.278076171875
▁bodies 0.955078125
▁will 0.80126953125
▁be 0.237060546875
▁cru 1.72265625
cial 0.0002416372299194336
▁in 0.71240234375
▁adv 4.05859375
ancing 0.001171112060546875
▁this 1.3193359375
▁ground 1.8916015625
- 2.294921875
bre 0.0004792213439941406
aking 0.00016260147094726562
▁ther 2.30859375
apy 0.00037288665771484375
▁towards 2.69921875
▁becoming 3.822265625
▁an 1.841796875
▁integral 1.74609375
▁part 0.2171630859375
▁of 0.0063934326171875
▁cancer 0.7255859375
▁treatment 0.170654296875
. 0.623046875
<0x0A> 0.14208984375
Con 5.5
clusion 0.30322265625
: 0.2230224609375
<0x0A> 2.80078125
The 1.615234375
▁positive 4.19921875
▁results 0.5361328125
▁show 6.390625
c 0.489990234375
ased 0.059234619140625
▁by 0.429443359375
▁[ 0.216064453125
Company 0.006214141845703125
▁Name 0.0066986083984375
] 0.032440185546875
' 0.546875
s 0.0031642913818359375
▁experimental 1.8447265625
▁cancer 0.11944580078125
▁drug 0.0706787109375
▁have 2.2109375
▁brought 2.630859375
▁renew 2.150390625
ed 0.00011360645294189453
▁hope 0.337158203125
▁to 0.62646484375
▁the 0.9931640625
▁cancer 3.818359375
▁community 1.1767578125
. 0.316650390625
▁While 1.322265625
▁anal 5.5546875
yst 0.00042891502380371094
s 0.0021762847900390625
▁ur 4.09375
ge 0.0035686492919921875
▁ca 0.0214996337890625
ution 2.181529998779297e-05
▁and 0.23046875
▁call 4.95703125
▁for 0.00698089599609375
▁further 0.1842041015625
▁research 0.14599609375
, 0.69970703125
▁the 1.4599609375
▁drug 1.5810546875
' 0.189208984375
s 0.0006914138793945312
▁effic 3.091796875
acy 1.633167266845703e-05
▁in 1.9189453125
▁in 6.01171875
hib 0.327392578125
iting 0.001216888427734375
▁tum 0.09222412109375
or 0.004543304443359375
▁growth 0.040740966796875
▁and 0.37841796875
▁impro 5.02734375
ving 0.0002579689025878906
▁patient 0.5419921875
▁out 0.86083984375
comes 0.044342041015625
▁cannot 6.28515625
▁be 0.0147552490234375
▁over 1.5
look 0.923828125
ed 2.384185791015625e-07
. 0.054779052734375
▁As 3.19140625
▁the 1.2880859375
▁drug 1.748046875
▁progress 2.3828125
es 0.004894256591796875
▁through 0.8681640625
▁more 4.55078125
▁compreh 4.82421875
ensive 0.0006165504455566406
▁tri 1.7802734375
als 4.839897155761719e-05
▁and 0.99072265625
▁regul 0.87109375
atory 0.0002849102020263672
▁appro 0.09442138671875
val 0.0001285076141357422
s 0.364501953125
, 0.0311126708984375
▁its 1.396484375
▁potential 0.8994140625
▁impact 2.787109375
▁on 0.25390625
▁cancer 0.84716796875
▁treatment 0.529296875
▁could 4.0546875
▁revolution 4.171875
ize 0.00159454345703125
▁the 0.52294921875
▁field 0.82763671875
▁and 2.64453125
▁offer 2.552734375
▁renew 4.84375
ed 0.0003025531768798828
▁prospect 7.42578125
s 0.0220184326171875
▁for 0.1942138671875
▁patients 0.6416015625
▁batt 4.21484375
ling 0.00012481212615966797
▁this 0.72216796875
▁dev 1.5361328125
ast 0.00018596649169921875
ating 0.0003707408905029297
▁disease 0.033203125
. 0.032623291015625
